Novel Therapeutic for the Treatment of COPD

OCR Number: OCR 4715

Description:

- Chronic Obstructive Pulmonary Disease (COPD), including emphysema and chronic bronchitis, leads to a major irreversible loss of lung function.
- COPD is the third leading cause of death in the US.
- A tremendous unmet medical need exists for effective treatment options for COPD.
- Inhibition of the IL-18 receptor (IL-18R) has been identified as a therapeutic intervention of COPD induced by cigarette smoke (CS).
- IL-18R signaling plays a critical role in the pathogenesis of CS-induced inflammation and emphysema.

In vivo studies using antibodies against IL-18R in animal models of COPD have demonstrated significant efficacy in reducing inflammation and cell death.

Published/Issued Patents: U.S. Pub. App. No. 20100247538

Licensing Contact: John Puziss
john.puziss@yale.edu